What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process

Barbara Farrell, Corey Tsang, Lalitha Raman-Wilms, Hannah Irving, James Conklin, Kevin Pottie, Barbara Farrell, Corey Tsang, Lalitha Raman-Wilms, Hannah Irving, James Conklin, Kevin Pottie

Abstract

Polypharmacy and inappropriate medication use among older adults contribute to adverse drug reactions, falls, cognitive impairment, noncompliance, hospitalization and mortality. While deprescribing - tapering, reducing or stopping a medication - is feasible and relatively safe, clinicians find it difficult to carry out. Deprescribing guidelines would facilitate this process. The aim of this paper is to identify and prioritize medication classes where evidence-based deprescribing guidelines would be of benefit to clinicians. A modified Delphi approach included a literature review to identify potentially inappropriate medications for the elderly, an expert panel to develop survey content and three survey rounds to seek consensus on priorities. Panel participants included three pharmacists, two family physicians and one social scientist. Sixty-five Canadian geriatrics experts (36 pharmacists, 19 physicians and 10 nurse practitioners) participated in the survey. Twenty-nine drugs/drug classes were included in the first survey with 14 reaching the required (≥ 70%) level of consensus, and 2 new drug classes added from qualitative comments. Fifty-three participants completed round two, and 47 participants completed round three. The final five priorities were benzodiazepines, atypical antipsychotics, statins, tricyclic antidepressants, and proton pump inhibitors; nine other drug classes were also identified as being in need of evidence-based deprescribing guidelines. The Delphi consensus process identified five priority drug classes for which expert clinicians felt guidance is needed for deprescribing. The classes of drugs that emerged strongly from the rankings dealt with mental health, cardiovascular, gastroenterological, and neurological conditions. The results suggest that deprescribing and overtreatment occurs through the full spectrum of primary care, and that evidence-based deprescribing guidelines are a priority in the care of the elderly.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Example histogram showing overall first…
Fig 1. Example histogram showing overall first round and personal results.
Fig 2. Participant flow diagram through three…
Fig 2. Participant flow diagram through three rounds of the Delphi consensus process.

References

    1. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012;344: e3502 10.1136/bmj.e3502
    1. Heath I. Overdiagnosis: when good intentions meet vested interests—an essay by Iona Heath. BMJ. 2013;347: f6361 10.1136/bmj.f6361
    1. Welch GH, Schwartz LM, Woloshin S. Overdiagnosed: Making People Sick in the Pursuit of Health. Boston: Beacon Press; 2011.
    1. Godlee F. Preventing overdiagnosis. BMJ. 2012;344: e3783 10.1136/bmj.e3783
    1. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5: 345–51. 10.1016/j.amjopharm.2007.12.002
    1. Ziere G, Dieleman JP, Hofman A, Pols HA, van der Cammen TJ, Stricker BH. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61: 218–23.
    1. Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012;29: 359–376. 10.2165/11599460-000000000-00000
    1. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26: 1039–48. 10.2165/11319530-000000000-00000
    1. Reason B, Terner M, McKeag MA, Tipper B, Webster G. The impact of polypharmacy on the health of Canadian seniors. Fam Pract. 2012;29: 427–32. 10.1093/fampra/cmr124
    1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365: 2002–12. 10.1056/NEJMsa1103053
    1. Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments, a retrospective study. Drug Saf. 2012;35: 769–781. 10.2165/11599540-000000000-00000
    1. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG.Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25: 1021–31. 10.2165/0002512-200825120-00004
    1. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SR. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28: 237–253. 10.1016/j.cger.2012.01.006
    1. Garfinkel D, Zur-Gil S, Ben-Israel J.The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007;9: 430–34.
    1. Anthierens S, Tansens A, Petrovic M, Christiaens T. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract. 2010;11: 65[6 p.]. 10.1186/1471-2296-11-65
    1. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30: 793–807. 10.1007/s40266-013-0106-8
    1. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: A systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26: 783–790. 10.1007/s11606-010-1629-x
    1. Wehling M. Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc. 2011;59: 376–77. 10.1111/j.1532-5415.2011.03252.x
    1. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60: 616–31. 10.1111/j.1532-5415.2012.03923.x
    1. O’Mahony D, Gallagher P, Ryan C, Byrne S, Hamilton H, Barry P, et al. STOPP and START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med. 2010;1: 45–51. 10.1016/j.eurger.2010.01.007
    1. Schunemman HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2014;186: E123–E142. 10.1503/cmaj.131237
    1. Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J. 2010. December 2010; 182:E839–842. 10.1503/090449
    1. Keeney S, Hasson F, Mckenna H. The Delphi Technique in Nursing and Health Research. West Sussex: John Wiley & Sons Ltd; 2010.
    1. Hamilton H, Gallagher PF, O’Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC Geriatr. 2009;9: 5 [4 p.] 10.1186/1471-2318-9-5
    1. Lane CJ, Bronskill SE, Sykora K, Dhalla IA, Anderson GM, Mamdani MM, et al. Potentially inappropriate prescribing in Ontario community-dwelling older adults and nursing home residents. J Am Geriatr Soc. 2004;52: 861–6.
    1. Canadian Institute for Health Information. Drug Claims by Seniors: An Analysis Focusing on Potentially Inappropriate Medication Use, 2000 to 2006. Canadian Institute for Health Information. 2007. Available: .
    1. Bierman AS, Pugh MJ, Dhalla I, Amuan M, Fincke BG, Rosen A, et al. Sex differences in inappropriate prescribing among elderly veterans. Am J Geriatr Pharmacother. 2007;5: 147–61.
    1. Ontario Drug Benefit Program. 2010/11 Report Card for the Ontario Drug Benefit Program. Ministry of Health and Long-Term Care. 2012. Available: .
    1. Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf. 2012;35: 769–81. 10.2165/11599540-000000000-00000
    1. Canadian Institute for Health Information. Adverse Drug Reaction-Related Hospitalizations Among Seniors, 2006 to 2011. Canadian Institute for Health Information. 2013. Available at:.
    1. Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56: 1946–52. 10.1111/j.1532-5415.2008.01916.x
    1. Sergi G, De Rui MD, Sarti S, Manzato E. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28: 509–18. 10.2165/11592010-000000000-00000
    1. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: “There’s got to be a happy medium”. JAMA. 2010;304: 1592–601. 10.1001/jama.2010.1482
    1. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170: 1648–54. 10.1001/archinternmed.2010.355
    1. bpacnz. A practical guide to stopping medicines in older people. Best Practice Journal 2010;27: [4 p.].
    1. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166: 605–9.
    1. Hardy JE and Hilmer SN. Deprescribing in the Last Year of Life. Journal of Pharmacy Practice and Research. 2011;41: 146–51.
    1. Le Couteur D, Banks E, Gnjidic D, McLachlan A. Deprescribing. Aust Prescr 2011;34: 182–5.
    1. Woodward MC. Deprescribing: Achieving Better Health Outcomes for Older People Through Reducing Medications. Journal of Pharmacy Practice and Research. 2003;33: 323–8.
    1. Gokula M and Holmes HM. Tools to reduce polypharmacy. Clin Geriatr Med. 2012;28: 323–41. 10.1016/j.cger.2012.01.011
    1. Voshaar RC, Couvee JE, van Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189: 213–20.
    1. Hsu CC and Sandford BA. The Delphi Technique: Making Sense of Consensus. Practical Assessment, Research and Evaluation. 2007;12: 10 [8 p.].
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64: 383–94. 10.1016/j.jclinepi.2010.04.026
    1. Hasson F, Keeney S and McKenna H.Research guidelines for the Delphi Survey. J Adv Nurs. 2000;32: 1008–15.
    1. Schmidt RC. Managing Delphi Surveys using nonparametric Statistical Techniques. Decision Sciences. 1997;28: 763–74.
    1. Field A. Non-parametric tests. In: Wright DB, editor. Discovering statistics using SPSS;2009. pp. 539–583.
    1. Pare G, Cameron AF, Poba-Nazaou P, Templier M. A systematic assessment of rigor in information systems ranking-type Delphi studies. Information & management. 2013;50: 201–217.
    1. Patton MQ. Qualitative Analysis and Interpretation. In: Laughton CD, editor. Qualitative Research and Evaluation Methods;2002. pp. 431–540.
    1. Hsieh H and Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15: 1277–1288.
    1. Holey EA, Feeley JL, Dixon J, Whittaker VJ. An exploration of the use of simple statistics to measure consensus and stability in Delphi studies. BMC Med Res Methodol. 2007;7: 52–62.
    1. American Geriatrics Society. AGS Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Society.2012. Available:
    1. Swinkels H, Pottie K, Tugwell P, Rashid M, Narasiah L; Canadian Collaboration for Immigrant and Refugee Health. Development of guidelines for recently arrived immigrants and refugees to Canada: Delphi consensus on selecting preventable and treatable conditions. CMAJ. 2011;183: e928–32. 10.1503/cmaj.09029
    1. Canadian Institute for Health Information. The Use of Selected Psychotropic Drugs Among Seniors on Public Drug Programs in Canada, 2001 to 2010. Canadian Institute for Health Information. 2012. Available: .
    1. Sithamparanathan K, Sadera A, Leung L. Adverse effects of benzodiazepine use in elderly people: a meta-analysis. Asian J Gerontol Geriatr. 2012;7: 107–11.
    1. Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204: 98–107. 10.1192/bjp.bp.113.126003
    1. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;3:CD007726 10.1002/14651858.CD007726.pub2
    1. Chokshi NP, Messerli FH, Sutin D, Supariwala AA, Shah NR. Appropriateness of Statins in Patients Aged ≥80 Years and Comparison to Other Age Groups. Am J Cardiol. 2012;110: 1477–81. 10.1016/j.amjcard.2012.06.058
    1. Byatt K. Overenthusiastic stroke risk factor modification in the over-80s: Are we being disingenuous to ourselves, and to our oldest patients? Evid Based Med 2014;19: 121–2. 10.1136/eb-2013-101646
    1. Mottram PG, Wilson K, Stobl J . Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;(1): CD003491
    1. Heidelbaugh JJ, Goldberg KL, Inadomi JM.Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16: e228–34
    1. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104 Suppl 2: S27–32. 10.1038/ajg.2009.49
    1. Spijker-Huiges A, Winters JC, Meyboom-De Jong B. Patients’ views on dyspepsia and acid suppressant drug therapy in general practice. Eur J Gen Pract. 2006;12: 10–4.
    1. Ott SM. What is the optimal duration of bisphosphonate therapy? Cleve Clin J Med. 2011;78: 619–30. 10.3949/ccjm.78a.11022
    1. Sykes L, Wood E, Kwan J. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev. 2014;1:CD005398 10.1002/14651858.CD005398.pub3

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner